TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival
Background and aims: TLR9 deletion protects against steatohepatitis due to choline–amino acid depletion and high-fat diet. We measured TLR9 in human non-alcoholic steatohepatitis (NASH) livers, and tested whether TLR9 mediates inflammatory recruitment in three murine models of non-alcoholic fatty liver disease (NAFLD). Methods: We assayed TLR mRNA in liver biopsies from bariatric surgery patients. Wild-type (Wt), appetite-dysregulated Alms1 mutant (foz/foz), Tlr9−/−, and Tlr9−/−.foz/foz C57BL6/J mice and bone marrow (BM) chimeras were fed 0.2% cholesterol, high-fat, high sucrose (atherogenic[Ath]) diet or chow, and NAFLD activity score (NAS)/NASH pathology, macrophage/neutrophil infiltration, cytokines/chemokines, and cell death markers measured in livers. Results: Hepatic TLR9 and TLR4 mRNA were increased in human NASH but not simple steatosis, and in Ath-fed foz/foz mice with metabolic syndrome-related NASH. Ath-fed Tlr9−/− mice showed simple steatosis and less Th1 cytokines than Wt. Tlr9−/−.foz/foz mice were obese and diabetic, but necroinflammatory changes were less severe than Tlr9+/+.foz/foz mice. TLR9-expressing myeloid cells were critical for Th1 cytokine production in BM chimeras. BM macrophages from Tlr9−/− mice showed M2 polarization, were resistant to M1 activation by necrotic hepatocytes/other pro-inflammatory triggers, and provoked less neutrophil chemotaxis than Wt. Livers from Ath-fed Tlr9−/− mice appeared to exhibit more markers of necroptosis [receptor interacting protein kinase (RIP)-1, RIP-3, and mixed lineage kinase domain-like protein (MLKL)] than Wt, and ∼25% showed portal foci of mononuclear cells unrelated to NASH pathology. Conclusion: Our novel clinical data and studies in overnutrition models, including those with diabetes and metabolic syndrome, clarify TLR9 as a pro-inflammatory trigger in NASH. This response is mediated via M1-macrophages and neutrophil chemotaxis.
Top-30
Journals
|
1
2
3
|
|
|
Frontiers in Endocrinology
3 publications, 4.11%
|
|
|
World Journal of Gastroenterology
2 publications, 2.74%
|
|
|
Nutrients
2 publications, 2.74%
|
|
|
International Journal of Molecular Sciences
2 publications, 2.74%
|
|
|
Frontiers in Immunology
2 publications, 2.74%
|
|
|
Nature Reviews Gastroenterology and Hepatology
2 publications, 2.74%
|
|
|
Liver Research
2 publications, 2.74%
|
|
|
Transplantation
1 publication, 1.37%
|
|
|
EMBO Molecular Medicine
1 publication, 1.37%
|
|
|
Experimental and Therapeutic Medicine
1 publication, 1.37%
|
|
|
Pharmaceutical Biology
1 publication, 1.37%
|
|
|
Cells
1 publication, 1.37%
|
|
|
Biomedicines
1 publication, 1.37%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 publication, 1.37%
|
|
|
Frontiers in Medicine
1 publication, 1.37%
|
|
|
Endocrine
1 publication, 1.37%
|
|
|
Scientific Reports
1 publication, 1.37%
|
|
|
International Journal of Obesity
1 publication, 1.37%
|
|
|
AMB Express
1 publication, 1.37%
|
|
|
Cellular and Molecular Immunology
1 publication, 1.37%
|
|
|
Life Sciences
1 publication, 1.37%
|
|
|
Molecular and Cellular Endocrinology
1 publication, 1.37%
|
|
|
Pharmacological Research
1 publication, 1.37%
|
|
|
Metabolism: Clinical and Experimental
1 publication, 1.37%
|
|
|
Free Radical Biology and Medicine
1 publication, 1.37%
|
|
|
Gastroenterology
1 publication, 1.37%
|
|
|
Journal of Nutritional Biochemistry
1 publication, 1.37%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 1.37%
|
|
|
Journal of Hepatology
1 publication, 1.37%
|
|
|
1
2
3
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
22 publications, 30.14%
|
|
|
Springer Nature
13 publications, 17.81%
|
|
|
Frontiers Media S.A.
9 publications, 12.33%
|
|
|
MDPI
7 publications, 9.59%
|
|
|
Baishideng Publishing Group
4 publications, 5.48%
|
|
|
Wiley
3 publications, 4.11%
|
|
|
European Molecular Biology Organization
2 publications, 2.74%
|
|
|
Spandidos Publications
2 publications, 2.74%
|
|
|
Taylor & Francis
2 publications, 2.74%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 2.74%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 1.37%
|
|
|
Hindawi Limited
1 publication, 1.37%
|
|
|
The Korean Association for the Study of the Liver
1 publication, 1.37%
|
|
|
American Physiological Society
1 publication, 1.37%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.37%
|
|
|
Oxford University Press
1 publication, 1.37%
|
|
|
OAE Publishing Inc.
1 publication, 1.37%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.